Tolerability. Efficacy. Accessibility.
By combining excellence in protein and adjuvant biology, we are focused on creating a new generation of non-mRNA adjuvanted subunit vaccines of global importance for the treatment and prevention of infectious diseases.
We focus on improved Tolerability, because no vaccine is protective unless people are willing to take it.
We focus on Efficacy, because developing safe and effective non-mRNA vaccines is central to our company focus.
We focus on Accessibility, because the only way a vaccine can reduce disease is if it is in sufficient supply and affordable.
curevo
About Our Team
Curevo has assembled a multidisciplinary team of dedicated professionals and scientific advisors who are experts in immunology, protein science, adjuvant technology, clinical trials, and regulatory operations.
Our shared goal is to reduce the burden of infectious disease, starting with shingles and chickenpox, and to address important unmet medical needs globally through our commitment to ushering safe, better-tolerated, and highly effective vaccines from the bench through clinical development and to market.
